Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

被引：8
|
作者：
Ozguroglu, Mustafa
Sezer, Ahmet
Kilickap, Saadettin
Gumus, Mahmut
Bondarenko, Igor
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Bentsion, Dmitry
Gladkov, Oleg
Clingan, Philip R.
Sriuranpong, Virote
Rizvi, Naiyer A.
McGinniss, Jennifer
Pouliot, Jean-Francois
Lee, Sue
Seebach, Frank A.
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
机构：
[1] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[2] Baskent Univ, Dept Med Oncol, Adana, Turkey
[3] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey
[4] Istanbul Medeniyet Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey
[5] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[6] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, GA USA
[7] Bezmialem Vakif Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey
[8] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[9] Sverdlovsk Reg Oncol Ctr, Dept Radiotherapy, Ekaterinburg, Russia
[10] LLC EVIMED, Chelyabinsk, Russia
[11] Univ Wollongong, Wollongong Hosp, Illawarra Canc Ctr, Southern Med Day Care Ctr, Wollongong, NSW, Australia
[12] Univ Wollongong, Wollongong Hosp, Illawarra Canc Ctr, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia
[13] Chulalongkorn Univ, Fac Med, Dept Med, Div Med Oncol, Bangkok, Thailand
[14] King Chulalongkorn Mem Hosp, Bangkok, Thailand
[15] Columbia Univ, Med Ctr, Div Hematol Oncol, New York, NY USA
[16] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9085
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Programmed Death Ligand 1 (PD-L1) Expression in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
    D'Arcangelo, M.
    Puccetti, M.
    Bravaccini, S.
    D'Incecco, A.
    Ligorio, C.
    Terracciano, L.
    Damiani, S.
    Ravaioli, S.
    Tumedei, M. M.
    Bennati, C.
    Minuti, G.
    Vecchiarelli, S.
    Landi, L.
    Incarbone, M.
    Milesi, M.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2390 - S2390
  • [32] Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer
    Jove, Maria
    Vilarino, Noelia
    Nadal, Ernest
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S364 - S368
  • [33] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
    Baramidze, Ana
    Makharadze, Tamta
    Gogishvili, Miranda
    Melkadze, Tamar
    Giorgadze, Davit
    Penkov, Konstantin
    Laktionov, Konstantin
    Nemsadze, Gia
    Nechaeva, Marina
    Rozhkova, Irina
    Kalinka, Ewa
    McIntyre, Debra A. G.
    Perez, Javier
    Kaul, Manika
    Quek, Ruben G. W.
    Seebach, Frank
    Rietschel, Petra
    Pouliot, Jean-Francois
    LUNG CANCER, 2024, 193
  • [34] Programmed Death Ligand-1 (PD-L1) Expression in Operable Non-Small Cell Lung Cancer (NSCLC) by Immunohistochemical Analysis
    Babayeva, Sabina
    Dyatlov, Artem
    Pallavi, Ranjita
    Fanucchi, Michael
    Puccio, Carmelo
    Lafaro, Rocco
    Shakil, Fouzia
    Fallon, John T.
    Zhong, Minghao
    LABORATORY INVESTIGATION, 2016, 96 : 467A - 467A
  • [35] Programmed Death Ligand-1 (PD-L1) Expression in Operable Non-Small Cell Lung Cancer (NSCLC) by Immunohistochemical Analysis
    Babayeva, Sabina
    Dyatlov, Arteni
    Pallavi, Ranjita
    Fanucchi, Michael
    Puccio, Carmelo
    Lafaro, Rocco
    Shakil, Fouzia
    Fallon, John T.
    Zhong, Minghao
    MODERN PATHOLOGY, 2016, 29 : 467A - 467A
  • [36] EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50%
    Sriuranpong, V.
    Altundag, O.
    Clingan, P.
    Rizvi, N.
    Frontera, O. Aren
    Sezer, A.
    Paydas, S.
    Shavdia, M.
    Bondarenko, I.
    Gladkov, O.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Spatiotemporal Effects on Programmed Death Ligand 1 (PD-L1) Expression and Immunophenotype of Non-Small Cell Lung Cancer (NSCLC)
    Kowanetz, Marcin
    Koeppen, Hartmut
    Boe, Marigold
    Chaft, Jamie E.
    Rudin, Charles M.
    Zou, Wei
    Nickles, Dorothee
    Desai, Rupal
    Nakamura, Rin
    Sandler, Alan
    Amler, Lukas
    Hegde, Priti
    Rizvi, Naiyer A.
    Hellmann, Matthew D.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S199 - S199
  • [38] Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence
    Lacour, Max
    Hiltbrunner, Stefanie
    Lee, Seok-Yun
    Soltermann, Alex
    Rushing, Elisabeth Jane
    Soldini, Davide
    Weder, Walter
    Curioni-Fontecedro, Alessandra
    CLINICAL LUNG CANCER, 2019, 20 (05) : 391 - 396
  • [39] PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement
    Isla, Dolores
    Sanchez, Alfredo
    Casal, Joaquin
    Cobo, Manuel
    Majem, Margarita
    Reguart, Noemi
    Zugazagoitia, Jon
    Bernabe, Reyes
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [40] JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)
    Ramalingam, S. S.
    Thara, E.
    Rao, S.
    Awad, M. M.
    Dowlati, A.
    Haque, B.
    Veatch, A. L.
    Stinchcombe, T.
    Dy, G. K.
    Spigel, D. R.
    Singh, N. Iyer
    Evilevitch, L.
    Wang, Z.
    Tang, Y.
    Teslenko, I.
    Roychoudhury, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S819 - S820
12345